Rollei Compactline 302

Bioscience Today Follow

News and insight into the UK's latest medical research and innovation. Published by @DistinctiveMed.

Bioscience Today @biosciencetoday ·

8 Mar

Kate Shaw, of @innovtrials, examines how broader representation in trial populations improves the validity and applicability of findings across diverse patient groups.

🔗 Read more: https://www.biosciencetoday.co.uk/inclusive-clinical-trials-will-drive-better-health-outcomes-for-all/

#ClinicalTrials #Inclusion

Reply on Twitter 2030576861252587531 Retweet on Twitter 2030576861252587531 Like on Twitter 2030576861252587531 Twitter 2030576861252587531

Bioscience Today @biosciencetoday ·

7 Mar

Precision oncology trials are poised to come into their own this year as targeted therapies, biomarker stratification and adaptive designs converge to improve outcomes, shares Dr Gen Li, CEO and Founder, @phesi_ct.

👉 Read more: https://www.biosciencetoday.co.uk/in-2026-precision-oncology-trials-will-finally-come-into-their-own/

#Oncology #ClinicalTrials

Reply on Twitter 2030199370100916656 Retweet on Twitter 2030199370100916656 Like on Twitter 2030199370100916656 Twitter 2030199370100916656

Bioscience Today @biosciencetoday ·

6 Mar

Europa Biosite Acquires Stratech Scientific, Expanding Their Product Offering and Strengthening UK Customer Reach @ams_bio

Reply on Twitter 2029951948355436779 Retweet on Twitter 2029951948355436779 Like on Twitter 2029951948355436779 Twitter 2029951948355436779

Bioscience Today @biosciencetoday ·

6 Mar

A new study, led by @ucl, links poorer heart health in middle age with increased dementia risk later in life, highlighting the long-term impact of cardiovascular health on brain function.

🔗 Read the study insights: https://www.biosciencetoday.co.uk/poorer-heart-health-in-middle-age-linked-to-increased-dementia-risk/

#HeartHealth #Dementia

Reply on Twitter 2029919980666429680 Retweet on Twitter 2029919980666429680 Like on Twitter 2029919980666429680 1 Twitter 2029919980666429680

Rollei Compactline 302

ABOUT US

FOLLOW US